Psyched Wellness (PSYC.C), a life sciences company focused on the production and distribution of functional and psychedelic mushrooms, announced today that it has contracted the Nation Research Council of Canada (NRC), an agency of the Government of Canada, to test the Company’s AME-1 extract.

“We are very proud to announce this agreement with the NRC, the results of this study will further demonstrate the tremendous potential with believe we have with AME-1 for people’s health and wellness,” says Jeffrey Stevens, CEO of the Company.

AME-1 is Psyched Wellness’ proprietary extract derived from the Amanita Muscaria mushroom, a fungi classified as poisonous with some psychedelic properties. However, the Company is exploring the potential health benefits of the AME-1 extract in a series of clinical trial. With this in mind, the NRC  specializes in providing vital scientific and technological services to research and industrial communities in Canada. In accordance with the contract, the NRC will provide its expertise in biomedical nanotechnology to study AME-1, but all results of the research will belong to Psyched Wellness.

With the NRC’s assistance, a study will be conducted over a period of 2 years to explore the neuroprotective, anti-inflammatory, and antioxidant nature of the AME-1 extract, concentrating on gut health and neuroprotection. Neuroprotection refers to the preservation of neuronal structure and function. Findings related to the neuroprotective properties of AME-1 would be essential in the discovering new health and wellness properties associated with the Amanita Muscaria mushroom.

I’ll be honest, gut health has never been something I have particularly cared about. However, gut health is associated with more than just your stomach and bowels. In fact, poor gut health can produce symptoms such as tiredness and problems sleeping as well as chronic conditions like Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS). Moreover, a healthy gut aids in digestion and the absorption of nutrients, which helps to regulate things like bile and vitamin levels, supporting one’s overall immune system.

“This investigative study will reveal key nutritional systematic and functional properties of the AME-1 extract. The Amanita Muscaria mushroom functional properties will be further investigated and identified in this scientific approach using modern scientific methods to help understand the functional neuroprotective and immune properties of AME-1,” says Brian Tancowny, scientific advisor to Psyched.

Even if you don’t fancy gut health, the digestive health products market may interest you. According to Grand View Research, this market is expected to reach USD$57.54 billion by 2025 with a compound annual growth rate (CAGR) of 7.3%. With that being said, there is undoubtedly a market for probiotics and digestive aids. If Psyched Wellness’ AME-1 studies are fruitful, the Company could potentially set foot in a highly profitable market.

Psyched Wellness’ share price opened at $0.24 and is currently trading at $0.24 as of 10:33AM ET. This indicates that there has not yet been any significant change following the news.

Written By:

Kieran Robertson

Kieran Robertson is an experienced writer with a passion for technology, esports, and video games. He graduated from the University of Western Ontario with a Major in English Language and Literature. After graduating, Kieran worked as a freelance writer, managing his own blog and volunteering for La Maza Magazine, a magazine startup focused on collaborating with photographers, writers, models, and designers.

More By This Author
Tags:
Biotech
Psychedelics
Robertson
amanita muscaria
AME-1
mushroom
PSYC.C
psyched wellness
Psychedelic
psychedelic mushroom
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments